GLP-1 Titration Protocols in Published Research

Titration is the single most under-discussed aspect of GLP-1 research protocol design. The pharmacology of semaglutide, tirzepatide, and retatrutide supports once-weekly dosing at the maintenance level, which is the form that pivotal trials report and the form clinical discussion focuses on. But the 12-16 weeks of gradual dose escalation that precede maintenance are where protocol failures happen, and where most of the tolerability data lives.

This article walks through the published titration schedules for all three compounds, explains the gastrointestinal tolerability biology that makes gradual titration non-negotiable, and covers the maintenance-phase decisions that determine whether a research protocol holds its effect after the escalation period ends.

Why titration is not optional

GLP-1 receptor agonism produces three well-characterised peripheral effects that together explain why dose escalation has to be gradual:

Delayed gastric emptying. GLP-1R activation on gastric smooth muscle slows the rate at which food exits the stomach. At target doses this produces the satiety that underlies the weight-loss endpoint. At the same target dose administered from day one, without adaptation time, it also produces persistent nausea, and in a meaningful subset of patients, vomiting. Drucker 2018 ⁷ covers the mechanism in detail as part of the broader review of GLP-1 pharmacology.

Central appetite suppression. Hypothalamic GLP-1R activation reduces food intake and produces the subjective sense of fullness. In the titration phase, this is the effect patients report as “not feeling hungry.” After the enteric nervous system adapts to delayed gastric emptying, the central signal is what the patient primarily experiences.

Enteric autonomic responses. The GI tract’s intrinsic nervous system (the enteric nervous system) responds to sustained GLP-1R activation with adaptive changes in motility and secretion patterns. This adaptation takes weeks. It does not happen at all if the dose is held at target from day one; it happens reliably if the dose escalates in small steps.

The titration schedules that clinical trial programmes arrived at are not arbitrary. They reflect the minimum escalation time needed for the enteric adaptation to occur reliably across a diverse patient population.

Semaglutide titration: the STEP regimen

Wilding and colleagues’ STEP 1 trial ¹ established the canonical semaglutide titration schedule for the obesity indication:

Total titration duration: 16 weeks. This is the headline fact that distinguishes obesity-indication semaglutide from diabetes-indication semaglutide. The diabetes regimen stops at 1.0 mg weekly, reached in 12 weeks. The obesity regimen continues to 2.4 mg, reached in 16 weeks.

Why does the escalation stop at 2.4 mg? Higher doses were tested and showed modest additional efficacy with disproportionate tolerability cost. The 2.4 mg weekly maintenance dose is the balance point the Phase 3 programme settled on. Protocols operating outside this dose range (research contexts using higher doses, or lower doses) should understand they are extrapolating from the 2.4 mg evidence base.

Common variations seen in research contexts:

• 4-week steps held to 6 weeks. Used when patients show GI intolerance at a dose level. Extending the step buys adaptation time.
• Skipping the 1.7 mg step. Some protocols go from 1.0 mg directly to 2.4 mg once the 1.0 mg is well-tolerated at 8+ weeks. Not the standard STEP approach but documented in post-STEP research as feasible in selected patients.
• Intermediate doses (0.75 mg, 1.2 mg). Custom-formulated for research protocols that want finer titration granularity. Not available in clinical formulations.

Tirzepatide titration: the SURMOUNT regimen

Tirzepatide titration is structurally similar to semaglutide’s but simpler in its increment pattern. Jastreboff and colleagues’ SURMOUNT-1 trial ² and Frías’ SURPASS-2 head-to-head against semaglutide ³ both used the same basic titration framework:

The 20-week timeline to reach 15 mg is longer than semaglutide’s 16 weeks to 2.4 mg, but the underlying principle is the same: 4-week steps with 2.5 mg increments throughout.

Dose decision points:

• Tirzepatide patients can stop at any 4-week plateau. Research protocols typically aim for the 10 or 15 mg dose, but 5 mg is the lowest approved therapeutic dose and has published efficacy data for specific indications (lower-BMI patients, T2DM with lower A1c elevation).
• Dose reduction is more flexible than with semaglutide because of the 2.5 mg increment pattern. Intolerance at 15 mg can drop back to 12.5 or 10 mg without creating a dose gap.

Coskun and colleagues’ 2018 Molecular Metabolism paper on the original tirzepatide discovery ⁶ characterised the pharmacology at multiple doses; the 20-week titration emerged from translating that preclinical dose-response into a clinically-tolerable escalation.

Retatrutide Phase 2 titration: less standardised

Retatrutide is still in Phase 2-3 transition. Jastreboff and colleagues’ 2023 Phase 2 NEJM trial ⁴ used four dose arms (1, 4, 8, 12 mg weekly) with titration schedules tailored to the target dose.

The broad pattern:

• Initial dose: 0.5 mg or 1 mg weekly for the first 4 weeks
• Escalation in 2-3 mg steps every 4 weeks to the target dose
• Highest-dose arm (12 mg weekly): reached over approximately 24 weeks

The difference from semaglutide and tirzepatide is the additional glucagon-receptor component. Glucagon-receptor activation increases hepatic glucose output and energy expenditure; in the titration phase, some patients report a distinctive sensation of warmth, mild tachycardia, and increased resting metabolic rate effects that the pure GLP-1 or dual GIP/GLP-1 compounds don’t produce. These effects appear to diminish with continued exposure in the same pattern as the GI effects diminish with titration on semaglutide and tirzepatide.

Phase 3 retatrutide work is ongoing and will settle the protocol-level titration specifics. Research protocols using retatrutide in 2025 should acknowledge that the titration schedule is less fully characterised than for semaglutide or tirzepatide, and design around the Phase 2 regimens while tracking emerging Phase 3 data.

The maintenance phase: STEP 4 and the durability question

Reaching the target dose is not the end of the protocol. The maintenance phase is where weight-loss effects either persist or attenuate. Rubino and colleagues’ STEP 4 trial ⁵ was specifically designed to address this question.

STEP 4 design:

• All patients completed a 20-week run-in with semaglutide 2.4 mg weekly (titration + initial maintenance)
• Responders who achieved at least 5% weight loss were randomised at week 20
• Randomisation: continue on 2.4 mg weekly vs switch to placebo
• Both groups received continued lifestyle intervention
• Primary endpoint: percentage body weight change from week 20 to week 68

STEP 4 results:

• Semaglutide-continued arm: additional 7.9% weight loss from week 20 to week 68
• Placebo arm: 6.9% weight regain from week 20 to week 68
• Net difference at 68 weeks: approximately 14.8% favouring continued semaglutide

The implications for research protocol design:

1. The effect is maintenance-dependent. The compound does not produce durable weight loss after discontinuation; it produces continuing weight loss under continuing exposure.
2. The weight-loss trajectory continues after titration. Patients continuing semaglutide at 2.4 mg lost additional weight through week 68 (beyond what they lost in titration). Plateau is not reached at the end of titration for most patients.
3. Protocols measuring final-state weight-loss effects need to extend through at least 48-68 weeks post-titration to capture the full effect. Shorter protocols measure a partial effect.

This maintenance-phase story is symmetric for tirzepatide and likely for retatrutide (though the latter’s data are less mature).

What happens when titration is skipped or compressed

Three failure patterns appear consistently in the research literature:

1. GI intolerance dropouts. Protocols that start patients directly at target dose produce dropout rates 2-3x higher than the titrated standard. The compounds work equivalently in patients who tolerate them; the titration phase selects for the patients who will tolerate target doses.

2. Artificial dose-response signals. Protocols comparing low vs high dose without equivalent titration periods may appear to show dose-response effects that are actually tolerability artifacts. If the low-dose arm reaches steady state in 4 weeks and the high-dose arm takes 16 weeks, the intermediate comparison is not dose-response; it’s time-to-steady-state.

3. Confounded maintenance measurements. Research protocols that stop at the end of titration (week 16 for semaglutide, week 20 for tirzepatide) measure the titration-phase effect, not the maintenance effect. This undershoots the clinical signal.

Research protocol design implications

For researchers using GLP-1 compounds:

1. Match titration to clinical precedent unless the research question requires deviation. Deviations should be justified and documented; the clinical titration schedule is the reference standard.

2. Budget protocol duration to include adequate maintenance. A 16-week protocol on semaglutide captures the titration effect, not the steady-state effect. Minimum reasonable duration is 24-32 weeks; STEP-equivalent is 68 weeks.

3. Track titration-phase adverse events separately from maintenance-phase events. GI events cluster in titration; cardiovascular and metabolic events reflect the maintenance exposure. Pooling them distorts the safety profile.

4. Consider dose-reduction protocols in advance. Build the decision rule into the protocol for what dose a patient drops to if they don’t tolerate an escalation step. Reactive decisions during the trial are harder to analyse.

5. Acknowledge the maintenance-dependent nature of the effect. Communication with patients and with downstream analysis should be clear that discontinuation produces weight regain. Post-protocol follow-up should be designed with this in mind.

Cross-compound comparison summary

Where to order

Buy Semaglutide, buy Tirzepatide, and buy Retatrutide from Thailand Peptides through the Bangkok research desk. Research-grade, ≥98% HPLC purity, supplier COA on file, same-week Thailand delivery.

For the broader GLP-1 class narrative, see the GLP-1 research overview. For the head-to-head trial comparison of semaglutide and tirzepatide, see the semaglutide vs tirzepatide trials deep-dive. For a use-case-level comparison including AOD-9604 and 5-Amino-1MQ, see best peptides for fat loss.